Ossur Third Quarter Report for 2007

Life Without Limitations

Press release from Ossur hf.

Reykjavik, 30 October 2007

Third Quarter 2007 Financial Highlights

- **Sales USD 82.3 million, up by 31% from Q3 2006**
- **Organic sales growth 11%**
- **Pro forma sales growth 11%**
- **EBITDA USD 14.1 million, up by 16% from Q3 2006**
- **EBITDA margin 17.1%, compared to 19.3% in Q3 2006**
- **Net profit USD 2.2 million, down from USD 5.4 million in Q3 2006**

First Nine Months 2007 Financial Highlights

- **Sales USD 250.7 million, up by 33% from 2006**
- **Organic sales growth 8%**
- **Pro forma sales growth 8%**
- **EBITDA USD 41.7 million, up by 23% from 2006**
- **EBITDA margin 16.6%, compared to 18.0% in 2006**
- **Net profit USD 0.9 million, compared to USD 8.1 million in 2006**

Jon Sigurdsson, President & CEO, comments:

"We are satisfied with our third quarter results. We continue to see impressive sales growth in Europe and are beginning to see positive results of our major restructuring of the bracing and support sales channels in the Americas earlier this year. Gibaud is progressing nicely and showing healthy growth from last year although we now have increased seasonality in our sales, due to summer closings in France. The strong double digit growth in prosthetics sales continues and there is a positive trend in our bracing and support sales. Overall, we are confident that we are now starting to harvest from our integration and restructuring efforts and have a solid foundation for future growth."

Quarterly Overview – Key Figures

Income Statements – Key Figures (USD '000)	Q3 2007	Q2 2007	Q1 2007	Q4 2006	Q3 2006
Net sales	82,322	88,037	80,380	63,844	62,755
Cost of goods sold	(33,561)	(34,916)	(34,394)	(26,945)	(24,946)
Gross profit	**48,761**	**53,121**	**45,986**	**36,899**	**37,809**
Other income	311	197	320	286	121
Sales & marketing expenses	(20,722)	(21,261)	(21,978)	(16,758)	(17,530)
Research & development expenses	(5,324)	(4,599)	(4,994)	(4,744)	(4,254)
General & administrative expenses	(14,901)	(16,082)	(15,277)	(9,785)	(9,085)
Restructuring expenses	0	0	0	(5,453)	0
Profit from operations	**8,125**	**11,376**	**4,058**	**444**	**7,061**
Financial income/(expenses)	(5,840)	(9,526)	(7,852)	(5,087)	(3,887)
Profit/(loss) before tax	**2,285**	**1,850**	**(3,794)**	**(5,363)**	**3,174**
Income tax	(130)	(367)	1,088	1,656	2,203
Net profit/(loss) for the period	**2,155**	**1,483**	**(2,706)**	**(3,707)**	**5,377**
EBITDA	14,068	17,353	10,240	5,617	12,138
EBITDA ratio	17.1%	19.7%	12.7%	8.8%	19.3%
EBITDA adjusted*	14,068	17,353	11,528	11,070	12,138
EBITDA ratio adjusted*	**17.1%**	**19.7%**	**14.3%**	**17.4%**	**19.3%**

* Adjusted for one time restructuring expenses and inventory step-up related to acquisitions

Operating Results for the Third Quarter of 2007

The operating results for the third quarter of 2007 are presented below. The Gibaud Group, acquired in December 2006 and Somas, acquired in February 2007, are both included in the consolidated accounts for the third quarter of 2007.

Income Statement Q3 2007 (USD '000)	Q3 2007	% of sales	Q3 2006	% of sales	Change
Net sales	82,322	100.0%	62,755	100.0%	31.2%
Cost of goods sold	(33,561)	-40.8%	(24,946)	-39.8%	34.5%
Gross profit	**48,761**	**59.2%**	**37,809**	**60.2%**	**29.0%**
Other income	311	0.4%	121	0.2%	157.0%
Sales & marketing expenses	(20,722)	-25.2%	(17,530)	-27.9%	18.2%
Research & development expenses	(5,324)	-6.5%	(4,254)	-6.8%	25.2%
General & administrative expenses	(14,901)	-18.1%	(9,085)	-14.5%	64.0%
Profit from operations	**8,125**	**9.9%**	**7,061**	**11.3%**	**15.1%**
Financial income /(expenses)	(5,840)	-7.1%	(3,887)	-6.2%	50.2%
Profit/(loss) before tax	**2,285**	**2.8%**	**3,174**	**5.1%**	**-28.0%**
Income tax	(130)	-0.2%	2,203	3.5%	-105.9%
Net profit for the period	**2,155**	**2.6%**	**5,377**	**8.6%**	**-59.9%**
EBITDA	**14,068**	**17.1%**	**12,138**	**19.3%**	**15.9%**

Sales

Ossur sales increased by 31% from the third quarter of 2006, measured in US dollars. Exchange rate trends had a positive impact on sales and growth measured in local currency was 27%.

Organic[1] sales growth was 11%, measured in US dollars and 8% measured in local currency. Pro forma sales growth, including Gibaud and Somas, was the same.

Seasonality in sales has increased following the acquisition of Gibaud, where operations close for 4-6 weeks in July and August for summer vacations. This has a negative effect on third quarter operations. Ossur sales decreased by 6% from the second quarter of 2007. Around two thirds of the decrease is directly related to Gibaud seasonality.

Product groups

The division of sales between main product groups during the third quarter was as follows:

USD '000	Q3 2007	Q3 2006	Growth USD	Growth LCY
Bracing & support	42,884	32,030	34%	30%
Prosthetics	35,146	30,591	15%	11%
Compression therapy	3,074	0	n/a	n/a
Other	1,218	134	809%	713%
Total	**82,322**	**62,755**	**31%**	**27%**

Bracing and support

Bracing and support sales increased by 34% from the third quarter of 2006. Both organic and pro forma growth was 5%, all measured in US dollars. Pro forma growth was 4% measured in local currency.

Organic growth in EMEA was double digits, both in US dollars and local currency. The increase in Gibaud's bracing and support sales was slightly less, although overall pro forma growth was healthy and exceeded market growth. The

[1] Organic growth is measured as the total revenue growth less acquired revenue from acquisitions and revenues from divested operations. Organic revenues for the quarter under review are calculated by deducting the revenues from businesses owned less than 15 full months from reported revenues. Organic revenue growth is determined by comparing the organic revenues for the quarter under review to the corresponding quarter one year earlier. The corresponding quarter one year earlier excludes any revenues from acquisitions made in that specific quarter.

major restructuring of the bracing and support sales channel in the Americas earlier this year is starting to show positive results and a steady increase in the growth trend.

Sales of bracing and support products accounted for 52% of total sales in the third quarter compared to 51% in 2006.

Prosthetics

Prosthetic sales continued to grow double digits for the third quarter in a row. Growth rates were excellent both in EMEA and Americas. Overall organic growth was 15%, measured in US dollars and 11% measured in local currency.

Sales of prosthetic products accounted for 43% of total sales compared to 49% in the third quarter of 2006.

Compression therapy

Gibaud's compression therapy sales increased by 8% from the third quarter of 2006, measured in US dollars. Sales growth was flat measured in local currency. Seasonality of compression therapy sales is exaggerated due to the structure of Gibaud's sales efforts, which periodically focus only on specific product groups.

Sales of compression therapy products accounted for 4% of total sales in the third quarter.

Geographical markets

The distribution of sales according to market regions during the third quarter of 2007 was as follows:

USD '000	Q3 2007	Q3 2006	Growth USD	Growth LCY
Americas	42,419	39,669	7%	7%
EMEA	36,904	20,132	83%	71%
Asia	2,999	2,954	2%	0%
Total	82,322	62,755	31%	27%

As of 1 January 2007, the Company has adopted a new geographical segmentation comprising of Americas, EMEA and Asia. Americas includes both North and South America, EMEA includes Europe, the Middle East and Africa and Asia also includes Australia. Comparison numbers for the third quarter of 2006 have been adjusted accordingly.

Americas

Sales in the Americas were up by 7% from the previous year, both when measured in US dollars and local currency. Organic and pro forma growth was the same.

Prosthetics sales continued to grow double digits and bracing and support sales growth is steadily improving following the major sales channel restructuring earlier this year.

Sales in the Americas accounted for 51% of sales, compared to 63% in the third quarter of 2006.

EMEA

Sales growth in Europe, Middle East and Africa was 83%, measured in US dollars and 71% measured in local currency. Organic growth and pro forma growth was an excellent 20% and 18% respectively, measured in US dollars and 12% and 10% measured in local currency.

Gibaud is on track with a pro forma sales increase of 7% compared to the third quarter of 2006, measured in local currency. As previously mentioned, seasonality in sales has increased following the acquisition of Gibaud, where operations close for 4-6 weeks in July and August for summer vacations. This has a negative effect on both sales and operating profit in EMEA as a large proportion of expenses is fixed.

Sales in EMEA accounted for 45% of total sales, compared to 32% in the third quarter of 2006.

Asia

Sales in Asia amounted to USD 3 million, representing 4% of total sales. Sales growth was flat measured in local currency.

In early October, Ossur Asia celebrated its first year of operations with an opening ceremony entertaining almost 200 guests, including the Icelandic President and Mr. Lu Shiming, Vice President of the China Disabled Persons' Federation.

Gross Profit

Gross profit amounted to USD 48.8 million compared to USD 37.8 million in the third quarter of 2006, increasing by 29%. The gross profit margin was 59.2% of sales compared to 60.2% in the third quarter of 2006.

Operating Expenses

Sales and marketing expenses amounted to USD 20.7 million or 25.2% of sales, compared to USD 17.5 million or 27.9% of sales in the third quarter of 2006. The main reason for the improvement is the turnaround in EMEA sales as well as the restructuring of the bracing and support sales channels in Americas. The lower sales and marketing cost ratio at Gibaud also contributes to the decrease.

Research and development expenses amounted to USD 5.3 million or 6.5% of sales, compared to USD 4.3 million or 6.8% of sales in the third quarter of 2006. The positive effect of economy of scale and the fact that the research and development cost ratio of Gibaud is considerably lower than historically at Ossur is partially offset by negative exchange rate effects, particularly the strengthening of the Icelandic krona against the US dollar. All internal research and development costs are expensed as incurred.

General and administrative expenses amounted to USD 14.9 million or 18.1% of sales, as compared to 9.1 million or 14.5% of sales in the third quarter of 2006. Exchange rate trends, unusual litigation expenses and the fact that Gibaud's G&A cost ratio is still significantly higher than historically at Ossur, all contribute to the increase.

Amortization of intangible assets relating to acquisitions amounted to USD 3.7 million, compared to USD 3.3 million in 2006. Amortization reduced the ratio of operating profit to sales in the third quarter of 2007 by 4.5 percentage points. The amount is allocated to individual operating items as follows:

Allocation of amortization of intangible assets to expense items	Q3 2007 USD '000	% of sales	Q3 2006 USD '000	% of sales
Sales and marketing expenses	2,066	2.5%	1,801	2.9%
Research & development expenses	1,127	1.4%	1,119	1.8%
General & administrative expenses	485	0.6%	367	0.6%
Effect on profit from operations	3,678	4.5%	3,287	5.2%

Amortization of intangible assets will continue at the same level for the next 3-4 years and then drop to a lower level for another 6 years. Further acquisitions will affect the amortization level.

Profit from Operations

Profit from operations in the third quarter of 2007 amounted to USD 8.1 million, compared to USD 7.1 million in 2006, increasing by 15%. The ratio of profit from operations to sales was 9.9%, decreasing from 11.3% in the third quarter of 2006. The slight decrease in gross profit margin and negative impact of general and administrative expenses were partially offset by the positive impact of a lower sales and marketing expenses ratio. The impact of exchange rate trends on profit from operations was minimal.

Financial Expenses

Net financial expenses amounted to USD 5.8 million in the third quarter of 2007, compared to USD 3.9 million in 2006, increasing by 50%.

Interest expenses on bank loans amounted to USD 6.9 million compared to USD 3.8 million in the third quarter of 2006, increasing by 80% mainly due to the addition of the bridge loan undertaken to finance the acquisition of Gibaud in December 2006.

Ossur has entered into an interest rate swap agreement fixing the rates of USD 140 million and EUR 48.6 million of the Company's long term debt at a weighted average of 5.99% per annum interest rate.

Approximately 65% of Ossur's long term bank loans are in US dollars and 35% in Euros. The 5% increase in the EUR/USD exchange rate from the beginning to the end of the quarter resulted in an approximately USD 3.9 million negative exchange rate difference on the Company's long term debt.

In August 2007 Ossur entered into currency hedging contracts, establishing a floor and ceiling to the amount of exchange rate differences on euro denominated debt. Late September the contracts were closed resulting in a USD 4.9 million gain which is realized through the profit and loss statement. Further hedging contracts have since been undertaken.

From 1 July 2007, exchange rate differences on the euro bridge loan are realized over equity against exchange rate gains on the relevant investment, in accordance with IFRS standard 39. The bridge loan is defined as a hedge against the euro investment in Gibaud. As a result, a negative exchange rate difference of USD 6.1 million was recognized through equity in the third quarter.

Income tax

Income tax amounted to USD 130 thousand for the second quarter, resulting in an effective tax rate of 5.7%. The extraordinary 69% positive tax rate in the third quarter of 2006 affects comparison of net results for the two quarters.

Profitability

EBITDA amounted to USD 14.1 million compared to USD 12.1 million in the third quarter of 2006, increasing by 16%. The ratio of EBITDA to sales was 17.1%, as compared to 19.3% in the third quarter of 2006. The slight decrease in gross profit margin and negative effect of seasonality at Gibaud are the main explanations.

Net profit before tax amounted to USD 2.3 million or 2.8% of sales as compared to USD 3.2 million and 5.1% of sales in the third quarter of 2006. In addition to already mentioned factors which negatively affect profit from operations compared to last year, the Company's increased leverage also has a significant negative impact on net profit before tax.

Net profit amounted to USD 2.2 million compared to USD 5.4 million in the third quarter of 2006, decreasing by 60%. The ratio of net profit to sales was 2.6%, as compared to 8.6% in the third quarter of 2006. The extraordinary 69% positive tax rate in the third quarter of 2006 affects comparison of net results.

Operating Results for the Nine Months of 2007

The operating results for the first nine months of 2007 are presented below. The Gibaud Group, acquired in December 2006, is included in the consolidated accounts for the first nine months and Somas from 1 February 2007.

Income Statement YTD 2007 (USD '000)	YTD 2007	% of sales	YTD 2006	% of sales	Change
Net sales	250,739	100.0%	188,289	100.0%	33.2%
Cost of goods sold	(102,870)	-41.0%	(75,811)	-40.3%	35.7%
Gross profit	**147,869**	**59.0%**	**112,478**	**59.7%**	**31.5%**
Other income	828	0.3%	244	0.1%	239.3%
Sales & marketing expenses	(63,961)	-25.5%	(50,862)	-27.0%	25.8%
Research & development expenses	(14,917)	-5.9%	(13,181)	-7.0%	13.2%
General & administrative expenses	(46,260)	-18.4%	(26,380)	-14.0%	75.4%
Restructuring expenses			(3,000)	-1.6%	
Profit from operations	**23,559**	**9.4%**	**19,299**	**10.2%**	**22.1%**
Financial income /(expenses)	(23,218)	-9.3%	(14,795)	-7.9%	56.9%
Profit / (loss) before tax	**341**	**0.1%**	**4,504**	**2.4%**	**-92.4%**
Income tax	591	0.2%	3,563	1.9%	-83.4%
Net profit for the period	**932**	**0.4%**	**8,067**	**4.3%**	**-88.4%**
EBITDA	**41,661**	**16.6%**	**33,877**	**18.0%**	**23.0%**

Organic sales growth in the first nine months of 2007 was 8% measured in US dollars and 5% measured in local currency. Pro forma sales growth was 8% measured in US dollars and 4% measured in local currency.

Sales in Americas increased by 5% measured in US dollars and organic growth was 4% for the first nine months of the year. The setback in growth has largely been due to the impact of the bracing and support sales channel restructuring program. Sales in EMEA increased by 87% measured in US dollars and 74% measured in local currency. Organic growth was 13% measured in US dollars and 5% measured in local currency. Pro forma sales growth was slightly lower, due to a negative impact of Gibaud. Sales growth in Asia was 15%.

Bracing and support sales increased by 38% from the first nine months of 2006 measured in US dollars, or 33% measured in local currency. Pro forma growth was 3% measured in US dollars and 1% measured in local currency. The sales growth trend has steadily been improving throughout the period. Prosthetics sales have increased double digits in all three quarters of the year, overall by 12% measured in US dollars and 9% measured in local currency.

Gross margin amounted to USD 147.9 million for the first nine months of 2007, increasing from USD 112.5 million in 2006 or by just short of 32%. The gross profit margin for the first nine months was 59.0% of sales, slightly down from 59.7% in 2006. Inventory step-up relating to the acquisition of the Gibaud Group amounted to USD 1.3 million in the first quarter of 2007, representing 0.5% of sales for the first nine months of the year.

Profit from operations was USD 23.6 million or 9.4% of sales, representing a 22% increase from the first nine months of 2006. The ratio of profit from operations to sales, excluding inventory step-up in the first quarter and USD 3 million in one-time restructuring expenses related to the acquisition of Innovation Sports in the first quarter of 2006, was 9.9% and 11.8% of sales for the first nine months of 2007 and 2006 respectively. Sales during the first quarter of the year were lower than expected, impacting the ratio of profit from operations to sales as a significant portion of operating expenses are fixed. Third quarter seasonality at Gibaud, severance payments related to the sales channel restructuring in Americas and litigation costs also had a negative impact on the ratio.

EBITDA amounted to USD 41.7 million compared to USD 33.9 million for the first nine months of 2006, increasing by 23%. The ratio of EBITDA to sales was 16.6% compared to 18.0% in 2006. The ratio of EBITDA to sales excluding inventory step-up and one-time restructuring expenses was 17.1% and 19.6% for the first nine months of 2007 and 2006 respectively.

The increase in interest expenses related to the bridge loan financing of the Gibaud acquisition and the negative exchange rate difference on the euro portion of the Company's bank loans had a significant negative impact on net profit for the first nine months of the year.

Balance Sheets

Consolidated Balance Sheets (USD '000)	30 September 2007	31 December 2006	Change
Fixed assets	491,751	489,319	0%
Current assets	133,317	123,433	8%
Total assets	**625,068**	**612,752**	**2%**
Stockholders' equity	171,089	161,639	6%
Long-term liabilities	233,661	234,538	0%
Current liabilities	220,318	216,575	2%
Total equity and liabilities	**625,068**	**612,752**	**2%**

Total assets have increased by USD 12.3 million from the end of 2006, or by 2%. The acquisition of Somas in February accounts for USD 11.0 million of the increase.

The equity ratio at the end of the third quarter was 27%, up one percentage point from the end of 2006. As previously communicated, the bridge loan undertaken to finance the acquisition of Gibaud in December 2006, is included in the Company's current liabilities. From 1 July 2007, exchange rate differences on the bridge loan are realized over equity against exchange rate gains on the investment in Gibaud.

Net interest bearing debt over estimated 2007 EBITDA is in the range of 6.5 to 7.0x.

Cash Flow

Cash Flow (USD '000)	YTD 2007	% of sales	YTD 2006	% of sales
Cash generated by operations, before interest and tax	37,150	45%	22,704	36%
Net cash provided by operating activities	25,719	31%	7,000	11%
Working capital provided by operating activities	12,811	16%	22,791	36%

Cash generated by operations, before interest and taxes, amounted to USD 37.2 million or 45% of sales, as compared to USD 22.7 million or 36% of sales in the third quarter of 2006, increasing by 64%.

Capital expenditure amounted to USD 4.7 million or 1.9% of sales, compared to USD 6.9 million or 3.6% of sales in the first nine months of 2006.

Earnings Per Share

Earnings per share	Q3 2007	Q3 2006	Change	YTD 2007	YTD 2006	Change
EPS diluted (US cents)	0.56	1.40	-60%	0.24	2.10	-88%
Cash EPS diluted (US cents)	2.10	2.72	-23%	4.94	5.89	-16%

Earnings per diluted share amounted to 0.24 US cents compared to 2.10 cents in the first nine months, decreasing by 88%, largely due to the increase in financial expenses.

Cash earnings per diluted share are measured as net profit plus depreciation and amortization per diluted share. Cash earnings per diluted share amounted to 4.94 US cents compared to 5.89 US cents in the first nine months of 2006, decreasing by 16%.

Five Year Comparison

Five Year Comparison (USD '000)	Q3 2007	Q3 2006	Q3 2005	Q3 2004	Q3 2003
Net sales	82,322	62,755	44,567	30,674	22,398
Profit from operations	8,125	7,061	1,686	5,511	2,942
Financial income / (expenses)	-5,840	-3,887	-1,861	210	-114
Profit (loss) before tax	2,285	3,174	-175	5,721	2,828
Net profit (loss)	2,155	5,377	812	4,678	2,266
Stockholders' equity	171,089	164,805	66,062	54,236	46,900
Total assets	625,068	453,597	396,454	107,977	101,731
Working capital from operating activities YTD	12,811	22,791	13,519	17,925	9,424
Cash provided by operating activities YTD	25,719	7,000	12,845	10,095	8,729
Return on common equity (LTM)	-2%	8%	20%	22%	20%
Current ratio	0.6	1.5	0.9	2.1	2.2
Equity ratio	27%	36%	17%	50%	46%
Earnings per share (US cents) (LTM)	-0.72	3.02	3.82	3.42	2.59
Price per share at end of quarter (ISK)	101.5	126.0	85.5	91.5	53.5
Market value at end of quarter (USD million)	630	692	441	410	231

Operating Prospects

The long term prospects for Ossur's operations are positive. Strong underlying market growth drivers include demographic aspects such as an aging population, increases in lifestyle diseases and more active and wealthy seniors. The significant investment in integration and restructuring efforts following the transformative acquisitions in 2005 and 2006 is starting to result in improved growth and operating performance. Management is confident that a solid foundation has been built for achieving the Company's ambitious growth targets.

Sales in the fourth quarter of 2007 are expected to be in the range of USD 85 to 87 million and EBITDA is expected to be in the range of USD 14 to 15 million.

Private Placement

Ossur's Board of Directors has authorized an increase in the Company's share capital by up to 10% through a private placement of shares to a limited number of institutional investors. The share capital increase will strengthen the Company's capital structure and expand the shareholder base. The private placement will be managed by Kaupthing Bank and take place today and tomorrow, 30-31 October 2007. A separate announcement on the public placement is published herewith.

Approval of Financial Statements

The Ossur hf. Consolidated Financial Statements for the first nine months of 2007 were approved at a meeting of the Board of Directors on 29 October 2007. The statements, prepared in compliance with International Financial Reporting Standards (IFRS), have been reviewed and endorsed by the Company's auditors without comments.

Investor Presentations

Today, Tuesday 30 October 2007, Jon Sigurdsson, President and CEO, and Hjorleifur Palsson, CFO will host a telephone conference for investors, analysts and shareholders at 13:00 GMT, 14:00 CET and 9:00 am Eastern Standard Time

The conference call can be heard on the Ossur website: www.ossur.com. Please call the following telephone numbers to participate in the conference:

Telephone number for Europe: +44 (0) 20 7162 0025
Telephone number for the United States: +1 334 323 6201

Queries can also be sent to the meeting held in English by e-mail to investormeeting@ossur.com.

At 16:15 GMT, there will be an open meeting with the Company's management at the Radisson SAS Hotel Saga in Reykjavik. Jon Sigurdsson, President and CEO, and Hjorleifur Palsson, CFO, will present and discuss the operations of the quarter.

Presentation material will be available on the Company's website (www.ossur.com) and the website of the OMX Nordic Exchange (www.omxgroup.com/nordicexchange/marketnews/companynotices).

Financial Calendar for 2007

The estimated dates of publication of interim and annual financial statements relating to 2007 are as follows:

Fourth quarter and 2007 annual results	**5 February 2008**
2008 Annual General Meeting	**22 February 2008**

Ossur press releases by e-mail

If you wish to receive Ossur press releases by e-mail please register at the following web-site: http://www.ossur.com/investormailings.

Further information

Jon Sigurdsson, President & CEO	**Tel: +354 515 1300**
Hjorleifur Palsson, CFO	**Tel: +354 515 1300**
Sigurborg Arnarsdottir, IR Manager	**Tel: +354 515 1300**

About Ossur
Ossur (Icelandic Stock Exchange: OSSR) is as much about helping people to live a *life without limitations* as it is about its orthopaedic products. A trusted and global leader in the development, manufacturing, distribution, sales and marketing of braces and support products, prosthetics and compression therapy, Ossur creates award-winning designs – including its bionic technologies – and partners with the health practitioners who use them to deliver successful clinical and business outcomes. With headquarters in Reykjavik, Iceland, the company has operations and a distribution network throughout the world. The company allocates 6-8% of its revenue to research and development to conceive and harness the most advanced technologies for incorporation in its product designs, and provides extensive education programs through the *Ossur Academy*. Website: www.ossur.com